Serum Levels of Uric Acid in Females of Polycystic Ovarian Syndrome with and without Insulin Resistance

Serum Levels of Uric Acid in Females of POCS


  • Adnan Riaz Department of Biochemistry, Islam Medical College, Sialkot, Pakistan
  • Faiza Ibrar Department of Biochemistry, Fatima Jinnah Medical University, Lahore, Pakistan
  • Tabinda Fatima Department of Biochemistry, Grand College of Pharmacy, Sialkot, Pakistan
  • Saadia Khanam Department of Gynecology and Obstetrics, Islam Medical College, Sialkot, Pakistan
  • Madiha Ashraf Department of Physiology, Post Graduate Medical Institute, Lahore, Pakistan
  • Ahmad Ashar Ghuman Department of Biochemistry, Sialkot Medical College, Sialkot, Pakistan



Polycystic Ovarian Syndrome, Insulin Resistance, Metabolic Syndrome, Uric Acid


Females suffering from polycystic ovarian syndrome have marked insulin resistance, independent of obesity. These women also have multiple risk factors for cardiovascular diseases, such as dyslipidemia, insulin resistance and hypertension. Uric acid level has also been recognized recently as a risk factor for cardiovascular diseases, females with PCOS may have abnormal profile of uric acid. Objectives: To compare uric acid levels in females of polycystic ovarian syndrome with and without insulin resistance. Methods: Cross-sectional comparative study was conducted in Biochemistry Department of Islam Medical College, Sialkot. Patients were divided into 2 groups based on their insulin resistance. In group-A patients were taken with PCOS and in group-B patients were taken with PCOS without insulin resistance. A total of 108 cases (54 in each group) fulfilling the inclusion/exclusion criteria. In both groups uric acid level was measured by standard procedure. Data were entered and analyzed using SPSS version 22 accordingly. Results: The mean age for all the cases was 29.43 ± 4.08 years, while mean age in insulin resistance group was 29.33 ± 4.06 years and mean age in non-insulin resistance group was 29.52 ± 4.13 years. The mean uric acid in insulin resistance and non-insulin resistance group was 4.92 ± 0.89 mg/dl and 4.48 ± 0.95 mg/dl with significantly higher mean uric acid in insulin resistance group, p-value < 0.05. Conclusion: We conclude that females having PCOS with insulin resistance had higher mean uric acid levels. Females with insulin resistance must be prevented from hyperuricemia to minimize the further risk of insulin resistance.


Barnard L, Ferriday D, Guenther N, Strauss B, Balen AH, Dye L. Quality of life and psychological well being in polycystic ovary syndrome. Human Reproduction. 2007 Jun; 22(8): 2279-86. doi: 10.1093/humrep/dem108

Ning N, Balen A, Brezina PR, Leong M, Shoham Z, Wallach EE, et al. How to recognize PCOS: results of a web-based survey at IVF-worldwide. com. Reproductive Biomedicine Online. 2013 May; 26(5): 500-5. doi: 10.1016/j.rbmo.2013.01.009

Zargar AH, Wani AI, Masoodi SR, Laway BA, Bashir MI, Salahuddin M. Epidemiologic and etiologic aspects of hirsutism in Kashmiri women in the Indian subcontinent. Fertility and Sterility. 2002 Apr; 77(4): 674-8. doi: 10.1016/S0015-0282(01)03241-1

Guler I, Himmetoglu O, Turp A, Erdem A, Erdem M, Onan MA, et al. Zinc and homocysteine levels in polycystic ovarian syndrome patients with insulin resistance. Biological Trace Element Research. 2014 Jun; 158(3): 297-304. doi: 10.1007/s12011-014-9941-7

Musmar S, Afaneh A, Mo'alla H. Epidemiology of polycystic ovary syndrome: a cross sectional study of university students at An-Najah national university-Palestine. Reproductive Biology and Endocrinology. 2013 Dec; 11(1): 1-6. doi: 10.1186/1477-7827-11-47

Devi SL and Jaweed SA. Homocysteine, c-reactive protein and traditional cardiovascular risk markers in polycystic ovary syndrome. International Journal of Current Research and Review. 2013 Mar; 5(6): 59-68.

Diamanti-Kandarakis E and Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews. 2012 Oct; 33(6): 981-1030. doi: 10.1210/er.2011-1034

Kanellis J and Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. InSeminars in nephrology 2005 Jan; 25(1): 39-42. WB Saunders. doi: 10.1016/j.semnephrol.2004.09.007

Cucuianu M and Brudasca I. Gout, hyperuricemia and the metabolic syndrome. Rev Romana Med Lab. 2012; 20(4): 1-8.

Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). American Journal of Physiology-Endocrinology And Metabolism. 2001 Aug; 281(2): E392-9. doi: 10.1152/ajpendo.2001.281.2.E392

Gul OO, Ersoy C, Gul B, Cander S, Unal OK, Erturk E, et al. Does uric acid predict insulin resistance in polycystic ovary syndrome?. In13th European Congress of Endocrinology. BioScientifica. 2011 Apr; 26.

Leuștean LE, Dimitriu C, Fica S, Ungureanu MC, Preda C, Mogoș V, et al. Serum Uric Acid Concentration in Overweight and Obese Women with Polycystic Ovary Syndrome. Romanian Review of Laboratory Medicine. 2015 Mar 1;23(1):107-14. doi: 10.1515/rrlm-2015-0010

Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM. Altered vascular function in young women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2002 Feb; 87(2): 742-6. doi: 10.1210/jcem.87.2.8199

Paradisi G, Steinberg HO, Shepard MK, Hook G, Baron AD. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2003 Feb; 88(2): 576-80. doi: 10.1210/jc.2002-020386

Rotterdam ESHRE/ASRM‐Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction. 2004 Jan; 19(1): 41-7. doi: 10.1093/humrep/deh098

Yaralı H, Yıldırır A, Aybar F, Kabakçı G, Bükülmez O, Akgül E, et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertility and Sterility. 2001 Sep; 76(3): 511-6. doi: 10.1016/S0015-0282(01)01937-9

Tzeng CR, Chang YC, Chang YC, Wang CW, Chen CH, Hsu MI. Cluster analysis of cardiovascular and metabolic risk factors in women of reproductive age. Fertility and Sterility. 2014 May; 101(5): 1404-10. doi: 10.1016/j.fertnstert.2014.01.023

Leustean L, Preda C, Ungureanu MC, Cristea C, Mogos V, Ungureanu D, et al. Main determinants of serum uric acid concentrations in polycystic ovary syndrome patients. In15th European Congress of Endocrinology. BioScientifica. 2013 Apr; 32. doi: 10.1530/endoabs.32.P607

Luque-Ramírez M, Alvarez-Blasco F, Uriol Rivera MG, Escobar-Morreale HF. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. Human Reproduction. 2008 Mar; 23(7): 1594-601. doi: 10.1093/humrep/den095

Li L, Zhang J, Zeng J, Liao B, Peng X, Li T, et al. Proteomics analysis of potential serum biomarkers for insulin resistance in patients with polycystic ovary syndrome. International Journal of Molecular Medicine. 2020 May; 45(5): 1409-16. doi: 10.3892/ijmm.2020.4522

Zhang Z, Hong Y, Chen M, Tan N, Liu S, Nie X, Zhou W. Serum metabolomics reveals metabolic profiling for women with hyperandrogenism and insulin resistance in polycystic ovary syndrome. Metabolomics. 2020 Feb; 16(2): 1-9. doi: 10.1007/s11306-020-1642-y

Song J, Ruan X, Gu M, Wang L, Wang H, Mueck AO. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology. 2018 May; 34(5): 413-7. doi: 10.1080/09513590.2017.1407752

Krysiak R, Szkróbka W, Okopień B. The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome. Pharmacological Reports. 2021 Feb; 73(1): 261-8. doi: 10.1007/s43440-020-00135-w

El-Eshmawy MM, Ibrahim A, Bahriz R, Shams-Eldin N, Mahsoub N. Serum uric acid/creatinine ratio and free androgen index are synergistically associated with increased risk of polycystic ovary syndrome in obese women. BMC Endocrine Disorders. 2022 Dec; 22(1): 1-8. doi: 10.1186/s12902-022-01240-y



DOI: 10.54393/pjhs.v4i01.502
Published: 2023-01-31

How to Cite

Riaz , A. ., Ibrar, F. ., Fatima, T. ., Khanam, S. ., Ashraf, M. ., & Ashar Ghuman, A. . (2023). Serum Levels of Uric Acid in Females of Polycystic Ovarian Syndrome with and without Insulin Resistance: Serum Levels of Uric Acid in Females of POCS . Pakistan Journal of Health Sciences, 4(01), 130–134.



Original Article